The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas.
The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas.
复制标题
DOI：
10.3389/fendo.2021.726448
复制
发表时间：
2021
影响因子：
5.2
通讯作者：
Zhang X
中科院分区：
文献类型：
--
作者：
Xi Z;Jones PS;Mikamoto M;Jiang X;Faje AT;Nie C;Labelle KE;Zhou Y;Miller KK;Soberman RJ;Zhang X
垂体腺瘤是最常见的颅内肿瘤之一。虽然这些肿瘤中的大多数是良性的，可以通过药物或经蝶手术治疗，但这些肿瘤的一个子集生长迅速，侵袭性强，复发，仍然是治疗的难题。由于针对免疫检查点受体PD-1和CLTA-4的抗体现在常规用于癌症治疗，我们定量了编码PD-1、CLTA-4及其配体PD-L1、PD-L2、CD 80和CD 86的mRNA在人垂体腺瘤和正常垂体中的表达，最终目标是在侵袭性垂体腺瘤中利用免疫检查点治疗。侵袭性垂体腺瘤中PD-L2、CD 80和CD 86的表达与正常人垂体相比有所增加。此外，与非侵袭性肿瘤相比，侵袭性垂体肿瘤表现出显著更高的CD 80和CD 86水平。我们的研究结果为研究免疫检查点抑制疗法在垂体腺瘤治疗中的潜在作用奠定了基础。
Human pituitary adenomas are one of the most common intracranial neoplasms. Although most of these tumors are benign and can be treated medically or by transsphenoidal surgery, a subset of these tumors are fast-growing, aggressive, recur, and remain a therapeutic dilemma. Because antibodies against immune checkpoint receptors PD-1 and CLTA-4 are now routinely used for cancer treatment, we quantified the expression of mRNA coding for PD-1, CLTA-4, and their ligands, PD-L1, PD-L2, CD80, and CD86 in human pituitary adenomas and normal pituitary glands, with the ultimate goal of exploiting immune checkpoint therapy in aggressive pituitary adenomas. Aggressive pituitary adenomas demonstrated an increased expression of PD-L2, CD80, and CD86 in compared to that of normal human pituitary glands. Furthermore, aggressive pituitary tumors demonstrated significantly higher levels of CD80 and CD86 compared to non-aggressive tumors. Our results establish a rationale for studying a potential role for immune checkpoint inhibition therapy in the treatment of pituitary adenomas.
登录
查看更多内容
PD-1，PD-1配体的关联以及肿瘤免疫微环境的其他特征与抗PD-1治疗的响应。
DOI：
10.1158/1078-0432.ccr-13-3271
发表时间：
2014-10-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Taube JM;Klein A;Brahmer JR;Xu H;Pan X;Kim JH;Chen L;Pardoll DM;Topalian SL;Anders RA
通讯作者：
Anders RA
影响因子：
51.1
作者：
Kato, Ken;Cho, Byoung Chul;Kitagawa, Yuko
通讯作者：
Kitagawa, Yuko
DOI：
10.1126/science.aad0095
发表时间：
2015-10-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Van Allen EM;Miao D;Schilling B;Shukla SA;Blank C;Zimmer L;Sucker A;Hillen U;Foppen MHG;Goldinger SM;Utikal J;Hassel JC;Weide B;Kaehler KC;Loquai C;Mohr P;Gutzmer R;Dummer R;Gabriel S;Wu CJ;Schadendorf D;Garraway LA
通讯作者：
Garraway LA
影响因子：
5.8
作者：
Lin, Andrew L.;Jonsson, Philip;Geer, Eliza B.
通讯作者：
Geer, Eliza B.
DOI：
10.1016/s0140-6736(16)00561-4
发表时间：
2016-05-07
期刊：
Lancet (London, England)
影响因子：
--
作者：
Rosenberg JE;Hoffman-Censits J;Powles T;van der Heijden MS;Balar AV;Necchi A;Dawson N;O'Donnell PH;Balmanoukian A;Loriot Y;Srinivas S;Retz MM;Grivas P;Joseph RW;Galsky MD;Fleming MT;Petrylak DP;Perez-Gracia JL;Burris HA;Castellano D;Canil C;Bellmunt J;Bajorin D;Nickles D;Bourgon R;Frampton GM;Cui N;Mariathasan S;Abidoye O;Fine GD;Dreicer R
通讯作者：
Dreicer R